



Credit photo : Franck Juery

# Servier Pipeline

April 2022










# ONCOLOGY – SOLID TUMORS

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
FTD/TPI combo bevacizumab	S95005	Solid tumors (new indication)	Worldwide ex-US/CAN, MEX & Asia	PCD 1 2 3	TAIHO ONCOLOGY
FTD/TPI combo futuximab / modotuximab	S95026	Solid tumors (new indication)	Worldwide ex-US/CAN, MEX & Asia	PCD 1 2 3	TAIHO ONCOLOGY
Vorasidenib	S95032	Low grade Glioma with IDH1/2 mutation	Worldwide	PCD 1 2 3	
Anti-MET	S95027	Non small Cell Lung Cancer	Worldwide	PCD 1 2 3	
Vorasidenib combo	S95032	Enhancing Grade 2-3 Glioma with IDH1/2 mutation	Worldwide	PCD 1/2 3	
Ivosidenib combo	S95031	Solid tumors (new indication)	Worldwide	PCD 1/2 3	
Anti-TIM3, anti-PD1, combo irinotecan	S95018	2 <sup>nd</sup> line Biliary Tract Cancer and Esophageal squamous cell carcinoma	Worldwide	PCD 1/2 3	
Anti-CD73	S95024	Solid tumors	Worldwide	PCD 1/2 3	
Anti-PD-L1/4-1BB	S95012	Solid tumors	Worldwide ex-US	PCD 1/2 3	pieris
NKG2A	S95029	Solid tumors	Worldwide	PCD 1/2 3	
MAT2A inhibitor (+ / - taxane-based chemotherapy)	S95033	1 <sup>st</sup> & 2 <sup>nd</sup> line Metastatic Pancreatic Ductal Adenocarcinoma and Esophageal squamous cell carcinoma with MTAP-deletion	Worldwide	PCD 1/2 3	
Anti-LAG3	S95017	Solid tumors	Worldwide	PCD 1/2 3	
MAT2A inhibitor	S95035	Solid tumors	Worldwide	PCD 1 2 3	

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, MOA = Mode of action

# ONCOLOGY – HEMATOLOGICAL MALIGNANCIES



Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
Ivosidenib combo azacitidine	S95031	Hematological malignancies (new indication)	Worldwide	PCD 1 2 3	Licensed in China  基石药业 ESTONE PHARMACEUTICALS
Ivosidenib combo 7+3 (chemo)	S95031	Hematological malignancies (new indication)	Worldwide	PCD 1 2 3	Licensed in China  基石药业 ESTONE PHARMACEUTICALS
UCART 19	S95023/S68587	Hematological malignancies	Worldwide ex-US	PCD 1 2 3	
Calaspargase pegol	S95015	Hematological malignancies (new indication)	Worldwide	PCD 1 2 3	
Pegaspargase	S95014	Hematological malignancies (new indication)	Worldwide	PCD 1 2 3	
Ivosidenib	S95031	Hematological malignancies (new indication)	Worldwide	PCD 1/2 3	Licensed in China  基石药业 ESTONE PHARMACEUTICALS
BCL-2 inhibitor	S65487	Acute Myeloid Leukemia (AML)	Worldwide ex-US/CAN, JAP, some EU countries	PCD 1/2 3	
Mcl1 inhibitor	S64315	Hematological malignancies	Worldwide ex-US/CAN, JAP, some EU countries	PCD 1/2 3	
Mcl1 inhibitor	S216096	Hematological malignancies	Worldwide ex-US/CAN, JAP, some EU countries	PCD 1 2 3	

# NEUROSCIENCE AND IMMUNO-INFLAMMATION

## NEUROSCIENCE

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
Agomelatine	S20098	Psychiatry (new indication)	Worldwide	PCD 1 2 3	
LRRK2	S221237	Parkinson's disease	Worldwide	PCD 1 2 3	

## IMMUNO-INFLAMMATION

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
Anti-IL7R	S95011	Sjögren syndrome	Worldwide	PCD 1 2 3	
Anti-IL7R	S95011	Ulcerative colitis	Worldwide	PCD 1 2 3	

# CARDIOMETABOLISM

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
NRF2	S227879	Non alcoholic steatohepatitis	Worldwide	PCD 1 2 3	